NCT06224309 2024-02-09
Preliminary Assessment of [18F]BL40 in PET/CT Scans
British Columbia Cancer Agency
Unknown
Clinical Trials
121 trialsNCT04663100 2023-12-04
Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence
University of Tennessee
Phase NA Unknown
NCT05803395 2023-11-28
Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.
Gruppo Italiano Malattie EMatologiche dell'Adulto
Unknown
NCT04754035 2023-10-03
IMPROVE
IRCCS San Raffaele
Phase 2 Unknown
NCT05020392 2023-07-25
Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3 Unknown
NCT02825836 2023-07-13
Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects
Telios Pharma, Inc.
Phase 1/2 Unknown
NCT04763083 2023-07-07
First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies
NovalGen Ltd.
Phase 1 Unknown
NCT04578613 2023-06-05
ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3 Unknown
NCT05888701 2023-06-05
"Don't Eat me" Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immunity.
University of Milano Bicocca
Unknown
NCT04356846 2023-05-01
A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase 1 Unknown
NCT04271410 2023-04-18
CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT04271800 2023-04-18
Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT05739227 2023-02-22
Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies
Xuzhou Medical University
Phase EARLY_PHASE1 Unknown
NCT05360758 2022-12-28
Ibrutinib Adapted to Response in Patients With CLL
Grupo Argentino de Tratamiento de la Leucemia Aguda
Unknown
NCT03280160 2022-09-16
Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab
PETHEMA Foundation
Phase 2 Unknown
NCT04502394 2022-08-04
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Kartos Therapeutics, Inc.
Phase 1/2 Unknown
NCT05410041 2022-06-08
Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies
Beijing Boren Hospital
Phase 1 Unknown
NCT05154474 2022-05-03
SPACE2
Weprom
Unknown
NCT05322733 2022-04-19
Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT05287984 2022-03-31
ZFCR/ZBR
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Unknown
NCT05003141 2022-03-28
PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
Phase 1 Unknown
NCT03529227 2022-02-14
GAIRI
Healthy Future
Unknown
NCT04640909 2022-01-04
Impact of Treatment With Targeted Therapies on the Generation of CAR T Cells in CLL Patients
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase NA Unknown
NCT03823365 2021-12-23
BET2017
A.O. Ospedale Papa Giovanni XXIII
Phase 1 Unknown
NCT05145101 2021-12-20
Pneumo-CLL
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Unknown
NCT05136378 2021-11-29
Selenious Yeast in CLL Patients w/o Indication of Chemotherapy
Shanghai Zhongshan Hospital
Phase NA Unknown
NCT04616274 2021-10-28
Pharmacokinetics of Venetoclax in Patients With Chronic Lymphocytic Leukemia
National Taiwan University Hospital
Unknown
NCT04862806 2021-09-17
Safety, Efficacy of BNT162b2 mRNA Vaccine in CLL
Bnai Zion Medical Center
Phase NA Unknown
NCT00003337 2021-08-16
Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma
Gilead Sciences
Phase 3 Unknown
NCT00003338 2021-08-16
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma
Gilead Sciences
Phase 2/3 Unknown
NCT04992377 2021-08-05
BDHRT001
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Unknown
NCT04370457 2021-08-04
MyPal ePRO-based Early Palliative Care System in Adult Patients With Hematologic Malignancies
Centre for Research and Technology Hellas
Phase NA Unknown
NCT04980859 2021-07-28
Zebutinib Combined With Immunochemotherapy in the Treat of Newly Treated CLL Patients Without 17p-/TP53 Mutation
Nanfang Hospital, Southern Medical University
Phase 3 Unknown
NCT04952974 2021-07-07
MALYZOMA-II
University Hospital, Strasbourg, France
Unknown
NCT01976520 2021-04-08
Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
XEME Biopharma Inc.
Phase 1 Unknown
NCT04796675 2021-04-08
Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1 Unknown
NCT04814004 2021-03-29
Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors
Xuzhou Medical University
Phase 1 Unknown
NCT04796688 2021-03-15
Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1 Unknown
NCT04767308 2021-02-23
Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies
Huazhong University of Science and Technology
Phase EARLY_PHASE1 Unknown
NCT03294980 2021-01-28
OFICE
University Hospital, Brest
Unknown
NCT04407845 2020-06-09
FABRIC
European Georges Pompidou Hospital
Unknown
NCT01619761 2020-02-11
NK Cells in Cord Blood Transplantation
M.D. Anderson Cancer Center
Phase 1 Unknown
NCT03633045 2020-02-10
Observational Study of Ibrutinib Use in CLL
Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health
Unknown
NCT03847727 2020-01-18
Bendamustine and Rituximab (BR) as Induction and Maintenance in Relapsed and Refractory Chronic Lymphocytic Leukemia
Pirogov Russian National Research Medical University
Unknown
NCT03110640 2019-11-27
Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma
First Affiliated Hospital of Wenzhou Medical University
Phase 1 Unknown
NCT04028440 2019-09-26
γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Unknown
NCT04094051 2019-09-18
Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice
The First Affiliated Hospital with Nanjing Medical University
Unknown
NCT03971565 2019-06-03
LLC
Assistance Publique Hopitaux De Marseille
Unknown
NCT00503256 2019-05-09
Genetic Study of Chronic Lymphocytic Leukemia Families
M.D. Anderson Cancer Center
Unknown
NCT03588598 2019-04-30
Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Phase 1 Unknown